Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/19/2008 10:19:52 AM
	of 10280

Sepracor upgraded to buy at UBS on attractive valuation, meaningful pipeline Thursday, June 19, 2008; Posted: 08:28 AM BOSTON, Jun 19, 2008 (Thomson Financial via COMTEX) -- SEPR \| Quote \| Chart \| News \| PowerRating -- Sepracor Inc. was upgraded Thursday to buy from neutral at UBS, which said the stock's valuation has become attractive with year-over-year earnings-per-share growth of about 40% estimated for 2009. "The flurry of business development activity in the last six months has provided product diversification, new avenues for growth and greater visibility into the company's strategy for franchise life beyond patent expirations," UBS said in a note to clients. The broker also said recent transactions have established a meaningful pipeline of late-stage products, with multiple catalysts beginning in the second half of 2008 and potential for upside. UBS maintained its price target of $25 on the stock but lowered its 2008 earnings-per-share estimate to $1.51 from $1.53 to incorporate franchise pressures. Analysts polled by Thomson Reuters, on average, estimate full-year earnings at Sepracor of $1.53 a share. Shares of the Marlborough, Mass.-based drug manufacturer closed Wednesday at $19.67.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next